474 related articles for article (PubMed ID: 26702849)
1. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Moody TW; Nuche-Berenguer B; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):38-47. PubMed ID: 26702849
[TBL] [Abstract][Full Text] [Related]
2. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
3. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Timely Top Med Cardiovasc Dis; 2005 Oct; 9():E33. PubMed ID: 16341283
[TBL] [Abstract][Full Text] [Related]
5. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
7. Early Alterations of PACAP and VIP Expression in the Female Rat Brain Following Spinal Cord Injury.
Broome ST; Mandwie M; Gorrie CA; Musumeci G; Marzagalli R; Castorina A
J Mol Neurosci; 2023 Oct; 73(9-10):724-737. PubMed ID: 37646964
[TBL] [Abstract][Full Text] [Related]
8. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
9. PACAP and its receptors in cranial arteries and mast cells.
Jansen-Olesen I; Hougaard Pedersen S
J Headache Pain; 2018 Feb; 19(1):16. PubMed ID: 29460121
[TBL] [Abstract][Full Text] [Related]
10. PAC1 receptors mediate pituitary adenylate cyclase-activating polypeptide- and progesterone-facilitated receptivity in female rats.
Apostolakis EM; Riherd DN; O'Malley BW
Mol Endocrinol; 2005 Nov; 19(11):2798-811. PubMed ID: 15976009
[TBL] [Abstract][Full Text] [Related]
11. PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium.
Girard BM; Malley SE; Braas KM; May V; Vizzard MA
J Mol Neurosci; 2010 Nov; 42(3):378-89. PubMed ID: 20449688
[TBL] [Abstract][Full Text] [Related]
12. A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.
Ramos-Álvarez I; Mantey SA; Nakamura T; Nuche-Berenguer B; Moreno P; Moody TW; Maderdrut JL; Coy DH; Jensen RT
Peptides; 2015 Apr; 66():26-42. PubMed ID: 25698233
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Drug News Perspect; 2005; 18(6):387-91. PubMed ID: 16247516
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
16. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors are present and biochemically active in the central nervous system of the pond snail Lymnaea stagnalis.
Pirger Z; Laszlo Z; Hiripi L; Hernadi L; Toth G; Lubics A; Reglodi D; Kemenes G; Mark L
J Mol Neurosci; 2010 Nov; 42(3):464-71. PubMed ID: 20396976
[TBL] [Abstract][Full Text] [Related]
18. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
